Literature DB >> 17975776

Bronchoalveolar lavage in sarcoidosis.

Marjolein Drent1, Khaled Mansour, Catharina Linssen.   

Abstract

There is no single cell type present in bronchoalveolar lavage (BAL) fluid that appears to be predictive for sarcoidosis. However, BAL fluid analysis can be very helpful in the differential diagnosis. A grouping of features, an elevated total cell count, predominantly lymphocytes, together with a nearly normal percentage of eosinophils and polymorphonuclear neutrophils and the absence of plasma cells, distinguish the most likely diagnosis of sarcoidosis from the most common interstitial lung diseases, extrinsic allergic alveolitis (EAA), nonspecific interstitial pneumonia (NSIP), and idiopathic pulmonary fibrosis (IPF). In sarcoidosis the majority of cases have an increased number of lymphocytes and a normal amount of eosinophils and neutrophils. Disease presentation or activity at the time the BAL is performed as well as the smoking status is crucial for interpretation of individual BAL fluid analysis results. In severe cases the number of neutrophils can be increased as well. For an individual case the CD4:CD8 ratio is of less importance because it can be increased, normal, and even decreased. In the follow-up depicting prognosis and response to treatment, BAL fluid analysis has less clinical relevance.

Entities:  

Mesh:

Year:  2007        PMID: 17975776     DOI: 10.1055/s-2007-991521

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  19 in total

1.  Bronchoalveolar lavage cell pattern from healthy human lung.

Authors:  M Heron; J C Grutters; K M ten Dam-Molenkamp; D Hijdra; A van Heugten-Roeling; A M E Claessen; H J T Ruven; J M M van den Bosch; H van Velzen-Blad
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Activated CD8(+) T cells and NKT cells in BAL fluid improve diagnostic accuracy in sarcoidosis.

Authors:  A Tøndell; A D Rø; A Åsberg; M Børset; T Moen; M Sue-Chu
Journal:  Lung       Date:  2013-11-10       Impact factor: 2.584

3.  Bronchoalveolar lavage total cell count in interstitial lung diseases--does it matter?

Authors:  Joanna Domagała-Kulawik; Tomasz Skirecki; Marta Maskey-Warzechowska; Hanna Grubek-Jaworska; Ryszarda Chazan
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

4.  Bronchoalveolar lavage characteristics correlate with HLA tag SNPs in patients with Löfgren's syndrome and other sarcoidosis.

Authors:  B Karakaya; M C Schimmelpennink; L Kocourkova; J J van der Vis; B Meek; J C Grutters; M Petrek; C H M van Moorsel
Journal:  Clin Exp Immunol       Date:  2019-01-24       Impact factor: 4.330

Review 5.  Bronchoalveolar lavage and other methods to define the human respiratory tract milieu in health and disease.

Authors:  Herbert Y Reynolds
Journal:  Lung       Date:  2011-02-25       Impact factor: 2.584

6.  Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action.

Authors:  H H Olsen; V Muratov; K Cederlund; J Lundahl; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

7.  Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease.

Authors:  E Fortunati; K M Kazemier; J C Grutters; L Koenderman; van J M M Van den Bosch
Journal:  Clin Exp Immunol       Date:  2008-12-09       Impact factor: 4.330

Review 8.  Pathology of Sarcoidosis.

Authors:  Giulio Rossi; Alberto Cavazza; Thomas V Colby
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

9.  Bronchoalveolar Lavage Fluid Characteristics of Patients With Sarcoidosis and Nonsarcoidosis Interstitial Lung Diseases: Ten-Year Experience of a Single Center in Turkey.

Authors:  Hakan Tanriverdi; Fatma Erboy; Bulent Altinsoy; Firat Uygur; Mehmet Arasli; Ishak Ozel Tekin; Muge Meltem Tor; Figen Atalay
Journal:  Iran Red Crescent Med J       Date:  2015-10-28       Impact factor: 0.611

10.  Improvement with infliximab of a disseminated sarcoidosis in a patient with Crohn's disease.

Authors:  Nader Chebib; Fabrice Piégay; Julie Traclet; François Mion; Jean-François Mornex
Journal:  Case Rep Pulmonol       Date:  2014-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.